Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RGS4 | P49798 | 1/20 | 0.44 |
| ▸ | RGS8 | P57771 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817364 | 0.92 | CCR2 (0.52) | CCR2ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL6086333 | 0.89 | CCR2 (0.55) | CCR2KDM4EHTTLMNAMAPT | |
| SCHEMBL6823866 | 0.86 | CCR2 (0.52) | CCR2HTTRGS4RGS8 | |
| SCHEMBL6085466 | 0.81 | CCR2 (0.67) | CCR2KDM4EHTTLMNATP53 | |
| SCHEMBL6084959 | 0.79 | MEN1 (0.49) | CCR2KDM4EHTTLMNATP53 | |
| SCHEMBL17831834 | 0.79 | MAPK1 (0.51) | CCR2ALDH1A1TDP1MAPK1SMN1; SMN2 | |
| SCHEMBL6820893 | 0.79 | CCR2 (0.64) | CCR2HPGDMAPTALDH1A1 | |
| SCHEMBL21335592 | 0.78 | ALDH1A1 (0.45) | CCR2KDM4EHPGDHTTLMNA | |
| SCHEMBL6086266 | 0.78 | HDAC1 (0.62) | CCR2KDM4EHTTLMNATP53 | |
| SCHEMBL9958735 | 0.77 | KDM4E (0.50) | CCR2KDM4EHPGDHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | TAKEUCHI KUMIKO (US) | 2004-01-15 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6410562-B1 | ANTIDIABETIC AGENTS | ELI LILLY AND COMPANY | 2002-06-25 | — | — | US | disclosed |
| WO-1999032482-A1 | HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0924209-A1 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009976-A1 | Hypoglycemic imidazoline compounds | GPR119, IAPP, GLP1R | CCR2 1775/4885KDM4E 2605/4885HPGD 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.